News

The third quarter results include after-tax special charges totaling $69 million (or $0.11 per diluted share) primarily for fixed asset write-offs related to the discontinuation of the company’s

Germany-based Merck and Dyesol have signed an agreement to collaborate in the development of electrolytes for use in Dye Solar Cells (DSC). Reportedly, this joint development agreement is

Mylan Pharmaceuticals (Mylan) has received approval from the FDA for its Abbreviated New Drug Application (ANDA) for Topiramate Capsules (Sprinkle), 15mg and 25mg. Topiramate Capsules (Sprinkle) are the

In January 2009, Tyrian reported that its lead TB marker was detected in clinical strains of the bacteria responsible for TB as well as in clinical sputum samples;

Bottomline Technologies has reported that Iroko Pharmaceuticals has selected Bottomline to extend and drive new capabilities from its Microsoft Dynamics AX 2009 implementation. The company has claimed that

Transposagen Biopharmaceuticals (Transposagen) has entered into an agreement to expand its license for piggyBac technology to cover nearly all commercial applications. Reportedly, as part of the licensing deal,

In their answer, Illumina and Solexa have denied all of Life Technologies’s and Applied Biosystems’s allegations of patent infringement, and have asserted that AB’s licensed patents are invalid.

Pfizer has entered into a settlement and license agreement with Mylan Pharmaceuticals and Matrix Laboratories subsidiaries relating to Voriconazole Tablets, 50 mg and 200 mg, the generic version

Suven Life Sciences’ has said that its clinical candidate SUVN-502 for Alzheimer’s Disease secured several product patents granted at all the key market countries; India (218438), Mexico (257091),